Skip to main content
SpringerLink
Log in

Modern Therapy for Paget’s Disease of Bone

Focus on Bisphosphonates

  • Review Article
  • Published:
Treatments in Endocrinology

Abstract

There has been a dramatic change in the therapeutic approach to patients with Paget’s disease of bone over the last 40 years. In the 1960s, only symptomatic therapy could be given, with control of pain the main objective. Analgesics and nonsteroidal anti-inflammatory drugs were the most commonly used agents. From 1968 onwards, antiosteoclastic agents became available, including calcitonin, plicamycin (mithramycin) and etidronate (etidronic acid), a first-generation bisphosphonate. Limitations with these agents, including potentially deleterious effects on bone mineralization with etidronate (etidronic acid), has cleared the way for increasingly potent second- and third-generation bisphosphonates, including clodronate (clodronic acid), pamidronate (pamidronic acid), alendronate (alendronic acid) and risedronate (risedronic acid). Even more potent bisphosphonates will become available in the near future.

With the newer bisphosphonates, there is some hope for long-term remission (if not definitive healing) of pagetic lesions, as well as prevention of long-term complications in both symptomatic and asymptomatic patients. Thus, indications for therapy have been extended to include younger patients to prevent bone deformity of the limbs and skull, leading to secondary osteoarthritis, facial deformities and potentially to sarcoma transformation; as well as to elderly patients to prevent bone fragility, leading to fracture, and pagetic vascular steal syndromes.

The increased potency and longer duration of action of newer bisphosphonates more than compensates for their marginally increased cost compared with older bisphosphonates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Fig. 1
Fig. 2
Table V
Table VI

Similar content being viewed by others

References

  1. Paget J. On a form of chronic inflammation of bones (osteitis deformans). Medico-Chirurgical Trans Lond 1877; 60: 37–63

    CAS  Google Scholar 

  2. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994; 4: 320–2

    Article  PubMed  CAS  Google Scholar 

  3. Jung A. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med 1982; 72: 221–5

    Article  PubMed  CAS  Google Scholar 

  4. Percival RC, Paterson AD, Yates AJ, et al. Treatment of malignant hypercalcaemia with clodronate. Br J Cancer 1985; 51: 665–9

    Article  PubMed  CAS  Google Scholar 

  5. Detheridge FM, Guyer PB, Barker DJP. European distribution of Paget’s disease of bone. BMJ 1982; 285: 1005–8

    Article  PubMed  CAS  Google Scholar 

  6. Guyer PB, Chamberlain AT. Paget’s disease of bone in two American cities [letter]. BMJ 1980; 280: 985

    Article  PubMed  CAS  Google Scholar 

  7. Altman RD, Bloch DA, Hochberg MC, et al. Prevalence of pelvic Paget’s disease of bone in the United States. J Bone Miner Res 2000; 15: 461–5

    Article  PubMed  CAS  Google Scholar 

  8. Kanis JA. Pathophysiology and treatment of Paget’s disease of bone. 2nd ed. London: Martin Dunitz, 1998

    Google Scholar 

  9. Pygott F. Paget’s disease of bone: the radiological incidence. Lancet 1957; I: 1170–1

    Article  Google Scholar 

  10. Harinck HIJ, Bijvoet OLM, Vellenga CJLR, et al. Relation between signs and symptoms in Paget’s disease of bone. Q J Med 1986; 226: 133–51

    Google Scholar 

  11. Cundy T, McAnulty K, Wattie D, et al. Evidence for secular changes in Paget’s disease. Bone 1997; 20: 69–71

    Article  PubMed  CAS  Google Scholar 

  12. Tiegs RD, Lohse CM, Wollan PC, et al. Long-term trends in the incidence of Paget’s disease of bone. Bone 2000; 27: 423–7

    Article  PubMed  CAS  Google Scholar 

  13. Cooper C, Schafheutle K, Dennison E, et al. The epidemiology of Paget’s disease in Britain: is the prevalence decreasing? J Bone Miner Res 1999; 14: 192–7

    Article  PubMed  CAS  Google Scholar 

  14. Van Staa TP, Selby P, Leufkens HGM, et al. Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 2002; 17: 465–71

    Article  PubMed  Google Scholar 

  15. Rapado A, Jimenez J, Morales A, et al. Patterns of diagnosis of Paget’s disease in Spain. J Bone Miner Res 1999; 14Suppl. 2: S96–8

    Article  Google Scholar 

  16. Nagant de Deuxchaisnes C, Devogelaer JP. Regional and heritable bone and collagen diseases: Paget’s disease of bone. In: Klippel JH, Dieppe PA, editors. Rheumatology. 2nd ed. London: Mosby, 1998: 45.1–45.6

    Google Scholar 

  17. Collins DH. Paget’s disease of bone: incidence and subclinical forms. Lancet 1956; II: 51–7

    Article  Google Scholar 

  18. Altman RD, Collins B. Musculoskeletal manifestations of Paget’s disease of bone. Arthritis Rheum 1980; 23: 1121–7

    Article  PubMed  CAS  Google Scholar 

  19. Winfield J, Stamp TCB. Bone and joint symptoms in Paget’s disease. Ann Rheum Dis 1984; 43: 769–73

    Article  PubMed  CAS  Google Scholar 

  20. Meunier PJ, Vignot E. Therapeutic strategy in Paget’s disease of bone. Bone 1995; 17: 489S–91S

    Article  PubMed  CAS  Google Scholar 

  21. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dyplasia of bone. Lancet 1994; 343: 953–4

    Article  PubMed  CAS  Google Scholar 

  22. Garnero P, Gineyts E, Schaffer AV, et al. Measurement of urinary excretion of nonisomerized and β-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget’s disease. Arthritis Rheum 1998; 41: 354–60

    Article  PubMed  CAS  Google Scholar 

  23. Nagant de Deuxchaisnes C. Medical management. In: DeGroot LJ, editor. Endocrinology. 2nd ed. Philadelphia (PA): WB Saunders Company, 1989: 1211–44

    Google Scholar 

  24. Nagant de Deuxchaisnes C, Devogelaer JP. Surveillance et suivi à long terme de la maladie osseuse de Paget. In: Simon L, Sébert JL, Hérisson Ch, editors. La Maladie Osseuse de Paget: Actualités. Paris: Masson, 1989

    Google Scholar 

  25. Delmas PD, Demiaux B, Malaval L, et al. Serum bone gla-protein is not a sensitive marker of bone turnover in Paget’s disease of bone. Calcif Tissue Int 1986; 38: 60–1

    Article  PubMed  CAS  Google Scholar 

  26. Maldague B, Malghem J. Dynamic radiologic patterns of Paget’s disease of bone. Clin Orthop 1987; 217: 126–51

    PubMed  Google Scholar 

  27. Nagant de Deuxchaisnes C, Maldague B, Malghem J, et al. The action of the main therapeutic regimes on Paget’s disease of bone, with a note on the effect of vitamin D deficiency. Arthritis Rheum 1980; 23: 1215–34

    Article  Google Scholar 

  28. Margiloff L, Harris SS, Lee S, et al. Vitamin D status of an outpatient clinic population. Calcif Tissue Int 2001; 69: 263–7

    Article  PubMed  CAS  Google Scholar 

  29. Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081–2

    Article  PubMed  CAS  Google Scholar 

  30. Wallach S. Calcitonin, history and prospects. Semin Arthritis Rheum 1994; 23: 256–60

    Article  PubMed  CAS  Google Scholar 

  31. Siris ES. Extensive personal experience: Paget’s disease of bone. J Clin Endocrinol Metab 1995; 80: 335–8

    Article  PubMed  CAS  Google Scholar 

  32. De Rose J, Singer FR, Avramides A, et al. Response of Paget’s disease to porcine and salmon calcitonin. Am J Med 1974; 56: 858–66

    Article  Google Scholar 

  33. Sturtridge WC, Harrison JE, Wilson DR. Long-term treatment of Paget’s disease of bone with salmon calcitonin. CMAJ 1977; 117: 1031–4

    CAS  Google Scholar 

  34. Bouvet J-P. Traitement de la maladie de Paget par la thyrocalcitonine de saumon: étude coopérative en double insu. Nouv Presse Med 1977; 6: 1447–50

    Google Scholar 

  35. Plehwe WE, Hudson J, Clifton-Bligh P, et al. Porcine calcitonin in the treatment of Paget’s disease of bone: experience with 32 patients. Med J Aust 1977; 1: 577–81

    PubMed  CAS  Google Scholar 

  36. Grunstein HS, Clifton-Bligh P, Posen S. Paget’s disease of bone: experiences with 100 patients treated with salmon calcitonin. Med J Aust 1981; 2: 278–80

    PubMed  CAS  Google Scholar 

  37. Manderlier T, Fuss M, Brauman J, et al. Traitement de la maladie de Paget par la calcitonine de saumon. Rev Rhum 1977; 44: 59–66

    PubMed  CAS  Google Scholar 

  38. Woodhouse NJY, Chalmers AH, Wells IP, et al. Paget’s disease: radiological changes occurring in untreated patients and those on therapy with salmon calcitonin during two years’ observation. Br J Radiol 1977; 50: 699–705

    Article  PubMed  CAS  Google Scholar 

  39. Murphy WA, Whyte MP, Haddad JG. Paget bone disease: radiologic documentation of healing with human calcitonin therapy. Radiology 1980; 136: 1–4

    PubMed  CAS  Google Scholar 

  40. Altman RD, Collins-Yudiskas B. Synthetic human calcitonin in refractory Paget’s disease of bone. Arch Intern Med 1987; 147: 1305–8

    Article  PubMed  CAS  Google Scholar 

  41. Singer FR, Fredericks RS, Minkin C. Salmon calcitonin therapy for Paget’s disease of bone. Arthritis Rheum 1980; 23: 1148–53

    Article  PubMed  CAS  Google Scholar 

  42. Wootton R, Reeve J, Spellacy E, et al. Skeletal blood flow in Paget’s disease of bone and its response to calcitonin therapy. Clin Sci Mol Med 1978; 54: 69–74

    PubMed  CAS  Google Scholar 

  43. Avramides A, Flores A, DeRose J, et al. Paget’s disease of the bone: observations after cessation of long-term synthetic salmon calcitonin treatment. J Clin Endocrinol Metab 1976; 42: 459–63

    Google Scholar 

  44. Evans IMA, Banks L, Doyle FH, et al. Paget’s disease of bone: the effect of stopping long term human calcitonin and recommendations for future treatment. Metab Bone Dis Relat Res 1980; 2: 87–91

    Article  Google Scholar 

  45. Nagant de Deuxchaisnes C, Devogelaer JP, Huaux JP, et al. Effect of a nasal spray of salmon calcitonin in normal subjects and in patients with Paget’s disease of bone. In: Pecile A, editor. Calcitonin. Amsterdam: Elsevier Science Publishers BV, 1985: 329–43

    Google Scholar 

  46. Nagant de Deuxchaisnes C, Devogelaer JP, Huaux JP, et al. New modes of administration of salmon calcitonin in Paget’s disease: nasal spray and suppository. Clin Orthop 1987; 217: 56–71

    PubMed  Google Scholar 

  47. Grauer A, Ziegler R, Raue F. Clinical significance of antibodies against calcitonin. Exp Clin Endocrinol 1995; 103: 345–51

    Article  CAS  Google Scholar 

  48. Nagant de Deuxchaisnes C. Development of alternative modes of administration of calcitonin. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress ApS, 1990: 1958–62

    Google Scholar 

  49. Devogelaer JP, Azria M, Attinger M, et al. Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue. Calcif Tissue Int 1994; 55: 71–3

    Article  PubMed  CAS  Google Scholar 

  50. Paget Foundation. Questions and answers about Paget’s disease of bone: a publication of the Paget Foundation for Paget’s disease of bone and related disorders. New York: The Paget Foundation, 2001

    Google Scholar 

  51. Canfield R, Rosner W, Skinner J, et al. Diphosphonate therapy of Paget’s disease of bone. J Clin Endocrinol Metab 1977; 44: 96–106

    Article  PubMed  CAS  Google Scholar 

  52. Alexandre C, Chapuy MC, Bressot C, et al. Traitement de la maladie osseuse de Paget par l’ethane-1 hydroxy-1,1 diphosphonate à faible posologie. Nouv Presse Med 1980; 9: 3429–33

    PubMed  CAS  Google Scholar 

  53. Khairi MRA, Altman RD, DeRosa GP, et al. Sodium etidronate in the treatment of Paget’s disease of bone: a study of long-term results. Ann Intern Med 1977; 87: 656–63

    PubMed  CAS  Google Scholar 

  54. Siris ES, Canfield RE, Jacobs TP, et al. Long-term therapy of Paget’s disease of bone with EHDP. Arthritis Rheum 1980; 23: 1177–84

    Article  PubMed  CAS  Google Scholar 

  55. Altman RD. Long-term follow-up of therapy with intermittent etidronate disodium in Paget’s disease of bone. Am J Med 1985; 79: 583–90

    Article  PubMed  CAS  Google Scholar 

  56. Gray RES, Yates AJP, Preston CJ, et al. Duration of effect of oral diphosphonate therapy in Paget’s disease of bone. Q J Med 1987; 64: 755–67

    PubMed  CAS  Google Scholar 

  57. Dodd GW, Ibbertson HK, Fraser TRC, et al. Radiological assessment of Paget’s disease of bone after treatment with the bisphosphonates EHDP and APD. Br J Radiol 1987; 60: 849–60

    Article  PubMed  CAS  Google Scholar 

  58. Vellenga CJLR, Pauwels EKJ, Bijvoet OLM, et al. Untreated Paget disease of bone studied by scintigraphy. Radiology 1984; 153: 799–805

    PubMed  CAS  Google Scholar 

  59. Alexandre C, Meunier PJ, Edouard C, et al. Effects of ethane-1 hydroxy-1,1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget’s disease of bone. Metab Bone Dis Rel Res 1981; 4 & 5: 309–16

    Article  Google Scholar 

  60. Kanis JA. Monitoring the treatment of Paget’s disease with etidronate. Calcif Tissue Int 1984; 36: 629–31

    Article  PubMed  CAS  Google Scholar 

  61. McCloskey EV, Yates AJP, Gray RES, et al. Diphosphonates and phosphate homeostasis in man. Clin Sci 1988; 74: 607–12

    PubMed  CAS  Google Scholar 

  62. Reginster JY, Gritten C, Diverse P, et al. Traitement de la maladie de Paget par l’etidronate disodique (EHDP) à faible dose (5 mg/kg par jour): apparition de leucopénies transitoires réversibles suspectes. Rev Rhum Mal Osteoartic 1985; 52: 145–50

    PubMed  CAS  Google Scholar 

  63. Drake WM, Kendler DL, Brown JP. Consensus statement on the modern therapy of Paget’s disease of bone from a Western Osteoporosis Alliance Symposium. Clin Ther 2001; 23: 620–6

    Article  PubMed  CAS  Google Scholar 

  64. Hosking DJ, Bijvoet OLM, van Aken J, et al. Paget’s bone disease treated with diphosphonate and calcitonin. Lancet 1976; I: 615–7

    Article  Google Scholar 

  65. Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, et al. Roentgenologic evaluation of the action of the diphosphonate EHDP and of combined therapy (EHDP and calcitonin) in Paget’s disease of bone. In: MacIntyre I, Szelke M, editors. Molecular endocrinology. Amsterdam: Elsevier/North-Holland Biomedical Press, 1979: 405–33

    Google Scholar 

  66. Douglas DL, Duckworth T, Kanis JA, et al. Biochemical and clinical responses to dichloromethylene diphosphonate (C12MDP) in Paget’s disease of bone. Arthritis Rheum 1980; 23: 1185–92

    Google Scholar 

  67. Delmas PD, Chapuy MC, Vignon E, et al. Long term effects of dichloromethylene diphosphonate in Paget’s disease of bone. J Clin Endocrinol Metab 1982; 54: 837–44

    Article  PubMed  CAS  Google Scholar 

  68. Yates AJP, Percival RC, Gray RES, et al. Intravenous clodronate in the treatment and retreatment of Paget’s disease of bone. Lancet 1985; I: 1474–7

    Article  Google Scholar 

  69. McCloskey EV, Yates AJP, Beneton MNC, et al. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 1987; 8Suppl. 1: S35–41

    PubMed  Google Scholar 

  70. Kanis JA, Preston CJ, Yates APJ, et al. Effects of intravenous diphosphonates on renal function. Lancet 1983; I: 1328

    Article  Google Scholar 

  71. Frijlink WB, Bijvoet OLM, Te Velde J, et al. Treatment of Paget’s disease with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (A.P.D.). Lancet 1979; I: 799–803

    Article  Google Scholar 

  72. Heynen G, Delwaide P, Bijvoet OLM, et al. Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget’s disease of bone. Eur J Clin Invest 1982; 11: 29–35

    Article  Google Scholar 

  73. Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, et al. Treatment of Paget’s disease with the diphosphonate APD: a biological and radiological study. In: Donath A, Courvoisier B, editors. Symposium CEMO IV ‘Diphosphonates and Bone’. Geneva: Editions Médecine et Hygiène, 1982: 303–27

    Google Scholar 

  74. Mautalen CA, Gonzalez D, Ghiringhelli G. Efficacy of the bisphosphonate APD in the control of Paget’s bone disease. Bone 1985; 6: 429–32

    Article  PubMed  CAS  Google Scholar 

  75. Harinck HIJ, Bijvoet OLM, Blanksma HJ, et al. Efficacious management with aminobisphosphonate (APD) in Paget’s disease of bone. Clin Orthop 1987; 217: 79–98

    PubMed  Google Scholar 

  76. Adamson BB, Gallacher SJ, Byars J, et al. Mineralisation defects with pamidronate therapy for Paget’s disease. Lancet 1993; 343: 1459–60

    Article  Google Scholar 

  77. Gutteridge DH, Retallack RW, Ward LC, et al. Clinical biochemical, hematologic and readiologic responses in Paget’s disease following intravenous pamidronate disodium: a 2-year study. Bone 1996; 19: 387–94

    Article  PubMed  CAS  Google Scholar 

  78. De Vries E, van der Weij JP, van der Veen CJP. In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mono-nuclear phagocytes in lymphocyte proliferation. Immunology 1982; 47: 157–63

    PubMed  Google Scholar 

  79. Thiebaud D, Jaeger P, Jacquet AJ, et al. Une perfusion unique de pamidronate (APD) dans la maladie de Paget de l’os. Schweiz Med Wochenschr 1989; 119: 71–4

    PubMed  CAS  Google Scholar 

  80. Chakravarty K, Merry P, Scott DGI. A single infusion of pamidronate AHPrBP in the treatment of Paget’s disease of bone. J Rheumatol 1994; 21: 2118–21

    PubMed  CAS  Google Scholar 

  81. Watts RA, Skingle SJ, Bhambhani MM, et al. Treatment of Paget’s disease of bone with single dose intravenous pamidronate. Ann Rheum Dis 1993; 52: 616–8

    Article  PubMed  CAS  Google Scholar 

  82. Cantrill JA, Buckler HM, Anderson DC. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget’s disease of bone. Ann Rheum Dis 1986; 45: 1012–8

    Article  PubMed  CAS  Google Scholar 

  83. Bombassei GJ, Yocono M, Raisz LG. Effects of intravenous pamidronate therapy on Paget’s disease of bone. Am J Med Sci 1994; 308: 226–33

    PubMed  CAS  Google Scholar 

  84. Anderson DC, Richardson PC, Kingsley Brown J, et al. Intravenous pamidronate: evolution of an effective treatment strategy. Semin Arthritis Rheum 1994; 23: 273–5

    Article  PubMed  CAS  Google Scholar 

  85. Fleisch H. Experimental basis for the use of bisphosphonates in Paget’s disease of bone. Clin Orthop 1987; 217: 72–8

    PubMed  Google Scholar 

  86. Dumon JC, Magritte A, Body JJ. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner 1991; 15: 257–66

    Article  PubMed  CAS  Google Scholar 

  87. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994; 118: 220–4

    PubMed  CAS  Google Scholar 

  88. Devogelaer JP, Triki R, Nagant de Deuxchaisnes C. Apparent versus true acquired resistance to pamidronate in Paget’s disease of bone. Bone Miner 1992; 17Suppl. 1: 67

    Google Scholar 

  89. Reginster JY, Colson F, Morlock G, et al. Evaluation of the efficacy and safety of oral tiludronate in Paget’s disease of bone. Arthritis Rheum 1992; 35: 967–74

    Article  PubMed  CAS  Google Scholar 

  90. Fraser WD, Stamp TC, Creek RA, et al. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget’s disease of bone. Postgrad Med J 1997; 73: 496–502

    Article  PubMed  CAS  Google Scholar 

  91. Morales-Piga A, Del Pino J, Rapado A, et al. Comparison of the efficacy and bioequivalence of two oral formulations of tiludronate in the treatment of Paget’s disease of bone. Clin Ther 1997; 19: 963–74

    Article  PubMed  CAS  Google Scholar 

  92. Neer RM. Skeletal safety of tiludronate. Bone 1995; 17: 501S–3S

    Article  PubMed  CAS  Google Scholar 

  93. Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget’s disease of bone. Arthritis Rheum 1995; 38: 851–8

    Article  PubMed  CAS  Google Scholar 

  94. Devogelaer JP, Malghem J, Stasse P, et al. Biological and radiological responses to oral etidronate and tiludronate in Paget’s disease of bone. Bone 1997; 20: 259–61

    Article  PubMed  CAS  Google Scholar 

  95. Nagant de Deuxchaisnes C, Dufour JP, Devogelaer JP. Etidronate and the risk of fractures. Lancet 1985; I: 610–1

    Article  Google Scholar 

  96. Lafuma A, Fagnani F, Meunier PJ. An economic evaluation of tiludronic acid treatment in Paget’s disease of bone. Pharmacoeconomics 1997; 12: 460–74

    Article  PubMed  CAS  Google Scholar 

  97. Adami S, Salvagno G, Guarrera G, et al. Treatment of Paget’s disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int 1986; 39: 226–9

    Article  PubMed  CAS  Google Scholar 

  98. Pedrazzoni M, Palummeri E, Ciotti G. Short-term effects on bone and mineral metabolism of 4-amino-1-hydroxybutylidene-1,1-diphosphonate (ABDP) in Paget’s disease of bone. Bone Miner 1989; 7: 301–7

    Article  PubMed  CAS  Google Scholar 

  99. O’Doherty DP, Bickerstaff DR, McCloskey EV, et al. Treatment of Paget’s disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res 1990; 5: 483–91

    Article  PubMed  Google Scholar 

  100. Adami S, Mian M, Gatti P, et al. Effects of two oral doses of alendronate in the treatment of Paget’s disease of bone. Bone 1994; 15: 415–7

    Article  PubMed  CAS  Google Scholar 

  101. Filipponi P, Pedetti M, Beghe F, et al. Effects of two different bisphosphonates on Paget’s disease of bone: ICTP assessed. Bone 1994; 15: 261–7

    Article  PubMed  CAS  Google Scholar 

  102. O’Doherty DP, McCloskey EV, Vasikaran S, et al. The effects of intravenous alendronate in Paget’s disease of bone. J Bone Miner Res 1995; 10: 1094–100

    Article  PubMed  Google Scholar 

  103. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone. J Clin Endocrinol Metab 1996; 81: 961–7

    Article  PubMed  CAS  Google Scholar 

  104. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiological improvement in Paget’s disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996; 171: 341–8

    Article  Google Scholar 

  105. Singer FR, Clemens TL, Eusebio RA, et al. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget’s disease. J Clin Endocrinol Metab 1998; 83: 1906–10

    Article  PubMed  CAS  Google Scholar 

  106. Hosking DJ, Eusebio RA, Chines AA. Paget’s disease of bone: reduction of disease activity with oral risedronate. Bone 1998; 22: 51–5

    Article  PubMed  CAS  Google Scholar 

  107. Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res 1998; 13: 1032–8

    Article  PubMed  CAS  Google Scholar 

  108. Brown JP, Hosking DJ, Ste-Marie LG, et al. Risedronate, a highly effective, short-term oral treatment for Paget’s disease: a-dose response study. Calcif Tissue Int 1999; 64: 93–9

    Article  PubMed  CAS  Google Scholar 

  109. Miller PD, Brown JP, Siris ES, et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Am J Med 1999; 106: 513–20

    Article  PubMed  CAS  Google Scholar 

  110. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42446, a new potent heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745–51

    Article  PubMed  CAS  Google Scholar 

  111. Arden-Cordone M, Siris ES, Lyles KW, et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget’s disease of bone. Calcif Tissue Int 1997; 60: 415–8

    Article  PubMed  CAS  Google Scholar 

  112. Woitge HW, Oberwittler H, Heichel S, et al. Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. Clin Chem 2000; 46: 684–90

    PubMed  CAS  Google Scholar 

  113. Adami S, Bevilacqua M, Broggini M, et al. Short-term intravenous therapy with neridronate in Paget’s disease. Clin Exp Rheumatol 2002; 20: 55–8

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author is grateful to Marie-Christine Hallot for her helpful assistance in the typing of the manuscript.

Author information

Authors and Affiliations

  1. Université Catholique de Louvain in Brussels, Brussels, Belgium

    Jean-Pierre Devogelaer

Authors
  1. Jean-Pierre Devogelaer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Pierre Devogelaer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Devogelaer, JP. Modern Therapy for Paget’s Disease of Bone. Mol Diag Ther 1, 241–257 (2002). https://doi.org/10.2165/00024677-200201040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024677-200201040-00006

Keywords

Search

Navigation